(Q33376008)

26 July 2017

title

Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma (English)

1 reference

26 July 2017

0 references

1 reference

11

Akira Sakai

1 reference

26 July 2017

Hirokazu Murakami

1

1 reference

26 July 2017

Hiroshi Handa

2

1 reference

26 July 2017

Masahiro Abe

3

1 reference

26 July 2017

Sinsuke Iida

4

1 reference

26 July 2017

Akihiro Ishii

5

1 reference

26 July 2017

Takayuki Ishikawa

6

1 reference

26 July 2017

Tadao Ishida

7

1 reference

26 July 2017

Masatsugu Oota

8

1 reference

26 July 2017

Shuji Ozaki

9

1 reference

26 July 2017

Masaaki Kosaka

10

1 reference

26 July 2017

Morio Sawamura

12

1 reference

26 July 2017

Chihiro Shimazaki

13

1 reference

26 July 2017

Kazuyuki Shimizu

14

1 reference

26 July 2017

Toshiyuki Takagi

15

1 reference

26 July 2017

Hiroyuki Hata

16

1 reference

26 July 2017

Takashi Fukuhara

17

1 reference

26 July 2017

Hiroshi Fujii

18

1 reference

26 July 2017

Akira Miyata

19

1 reference

26 July 2017

Toshio Wakayama

20

1 reference

26 July 2017

Kiyoshi Takatsuki

21

1 reference

26 July 2017

publication date

26 July 2007

1 reference

European Journal of Haematology

26 July 2017

published in

1 reference

26 July 2017

volume

79

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

234-239

1 reference

Single versus double autologous stem-cell transplantation for multiple myeloma.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Thalidomide: a novel template for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Low-dose thalidomide in myeloma: efficacy and biologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Thalidomide: A review of approved and investigational uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Thalidomide and low-dose dexamethasone in myeloma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

Thalidomide-associated deep vein thrombosis and pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00908.X

10.1111/J.1600-0609.2007.00908.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference